LITHA HEALTHCARE GROUP LIMITED - Changes to the board of directors

Release Date: 10/10/2014 16:23
Code(s): LHG
 
Wrap Text
Changes to the board of directors

LITHA HEALTHCARE GROUP LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2006/006371/06)
Share code: LHG
ISIN: ZAE000144671
(”Litha”)

CHANGES TO THE BOARD OF DIRECTORS

In compliance with section 3.59 of the Listings Requirements of the JSE Limited,
shareholders are advised that Suketu Upadhyay and Hemanth Varghese have been
appointed as non-executive directors with effect from 10 October 2014.

Suketu “Suky” Upadhyay, Executive Vice President and Chief Financial Officer, joined Endo
September 2013. Prior to joining Endo, since 2010, Mr. Upadhyay served as Interim Chief
Financial Officer as well as Senior Vice President of Finance and Corporate Controller of
Becton, Dickinson & Co (BD). In addition to other executive finance roles at BD, from 2007
to 2010, he served in various finance leadership roles at AstraZeneca and Johnson &
Johnson. Mr. Upadhyay spent the early part of his career in public accounting with KPMG
and received his CPA in May 1996. He received a Bachelor of Science in Finance from
Albright College and received a Master of Business Administration from The Fuqua School
of Business at Duke University.

Hemanth J. Varghese, Ph.D. joined Endo in April 2014 as Executive Vice President
Corporate Development and Strategy to lead the company’s global acquisitions and
integration efforts. Dr. Varghese brings to Endo a successful track record in corporate
development and general management in specialty pharmaceuticals, most recently serving
as the Senior Vice President and General Manager of Vision Care for Bausch & Lomb, a
division of Valeant Pharmaceuticals. During his tenure with Valeant, Dr. Varghese held
various senior leadership roles including Senior Vice President of Corporate Development
and General Manager of Valeant's Neurology & Other business unit. Over his career he has
completed more than 40 corporate transactions, leading corporate development and
integration initiatives including public/private acquisitions, investments, partnerships,
licenses and divestitures. Prior to joining Valeant, Dr. Varghese served in corporate
development and operations leadership roles at Biovail Corporation, JovInvestment
Management Inc., and Robarts Research Institute. He obtained his BSc degree with honors
in Biophysics and PhD in Medical Biophysics from the University of Western Ontario and
holds the Charted Financial Analyst designation.

Mark Nawacki and Mark Beaudet have resigned as non-executive directors with effect from
10 October 2014. The Board would like to thank them for their valuable contribution.

Midrand
10 October 2014

Sponsor
One Capital

Date: 10/10/2014 04:23:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Email this JSE Sens Item to a Friend.

Share This Story